Paediatric formulation: budesonide 0.1 mg/mL viscous oral solution for eosinophilic esophagitis using cyclodextrins
Viscous oral solutions of budesonide (dose range: 1 mg to 2 mg) have long been used to treat eosinophilic oesophagitis in children. The objective of the present study was to provide a convenient paediatric pharmaceutical formulation of a viscous budesonide solution at a dose level of 0.1 mg/mL, usin...
Saved in:
Main Authors: | Ey Caroline (Author), Hosselet Christel (Author), Villon Benjamin (Author), Marçon Frédéric (Author) |
---|---|
Format: | Book |
Published: |
De Gruyter,
2018-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Similar Items
-
Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia
by: Raffaele Simeoli, et al.
Published: (2024) -
Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis
by: Antonella Casiraghi, et al.
Published: (2020) -
Mucoadhesive Budesonide Solution for the Treatment of Pediatric Eosinophilic Esophagitis
by: Antonio Spennacchio, et al.
Published: (2024) -
The Design of Novel 3D-Printed, Moulded, and Oral Viscous Budesonide Formulations for Paediatrics: A Comparative Evaluation of Their Mucoadhesive Properties
by: María Magariños-Triviño, et al.
Published: (2024) -
Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension
by: Stacie Hudgens, et al.
Published: (2017)